Search

Search Constraints

You searched for: Author/Creator Kuribayashi, Nobuichi

Search Results

1. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

2. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

3. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

4. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

5. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

6. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

7. Applications of physical performance measures to routine diabetes care for frailty prevention concept: fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. Issue 1 (18th September 2020)

8. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). Issue 5 (9th May 2017)

9. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial. Issue 2 (24th September 2014)

10. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor sitagliptin compared with alpha‐glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin‐1): A multicenter, randomized, open‐label, non‐inferiority trial. Issue 2 (24th September 2014)